INTRODUCTION
The chimeric anti-CD20 monoclonal antibody, rituximab, was initially approved for treating relapsed or refractory low-grade or follicular CD20 ϩ , B-cell non-Hodgkin's lymphoma (NHL). 1 Since then, rituximab use has expanded in NHL, [2] [3] [4] primarily in combination with chemotherapy, [5] [6] [7] [8] [9] [10] and applied in autoimmune disorders, 11-14 whereas second-generation anti-CD20 antibodies have been constructed in attempts to increase efficacy, decrease toxicity (primarily infusion reactions) or immunogenicity, and allow more rapid administrations. [15] [16] [17] [18] [19] [20] Veltuzumab (hA20) is a humanized, anti-CD20 monoclonal antibody with both structural and functional differences from rituximab.
21,22
The first clinical use of veltuzumab was in a patient with lupus who had life-threatening cytopenias no longer responsive to standard medications or rituximab. Despite extremely high serum levels of antirituximab antibodies (43,000 ng/mL), veltuzumab effectively depleted B cells and the patient clinically responded rapidly. 23 In mice-bearing human lymphoma xenografts, low doses of veltuzumab controlled tumor growth, even producing a number of cures. 22 This dosefinding study was undertaken in NHL, demonstrating excellent safety and objective responses with veltuzumab at all dose levels tested, including doses less than those typically used with rituximab.
PATIENTS AND METHODS
This was an open-label, multicenter, phase I/II study in patients with refractory or recurrent NHL. The primary objectives were to evaluate the safety, tolerance, and immunogenicity of veltuzumab, whereas the secondary objectives were to obtain preliminary evidence of efficacy and to assess pharmacokinetics and pharmacodynamics. The initial dose escalation treated three to six patients at dose levels from 120 mg/m 2 to 750 mg/m 2 . 24 After objective responses (including complete response [CR] and CR unconfirmed [CRu] ) occurred at all levels without obvious dose response, 25 the cohorts at 120, 200, and 375 mg/m 2 were expanded by at least 10 additional patients to achieve the study objectives while the protocol was amended to assess the activity of an even lower dose (80 mg/m 2 ).
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Patients
Eligible patients were Ն 18 years of age with CD20 ϩ histologically confirmed B-cell NHL and progressive disease after one or more prior standard chemotherapy or rituximab-containing regimen (but no progression within 6 months of rituximab). Patients also had to have one or more measurable lesions Ն 1.5 cm by computed tomography (but none Ͼ 10 cm), Eastern Cooperative Oncology Group performance status Յ 2, hemoglobin Ն 10 g/dL, absolute neutrophil count Ն 1.5 ϫ 10 9 /L, platelets Ն 100 ϫ 10 9 /L (all without transfusional support), creatinine and bilirubin Յ 1.5ϫ institutional upper limit of normal, AST and ALT Յ 2.5ϫ institutional upper limit of normal, and be 5 years beyond any other cancers (except nonmelanoma skin cancer or cervical carcinoma in situ), 12 weeks beyond any autologous stemcell transplantation, and with no chemotherapy, other experimental treatments, or any radiation therapy to the index lesion(s) within 4 weeks or corticosteroids within 2 weeks. Patients with symptomatic CNS lymphoma; known HIV, hepatitis B, or hepatitis C positivity; known human antichimeric antibody positivity (testing was not required); or prior therapy with other human or humanized monoclonal antibodies (unless human antiveltuzumab antibody [HAHA] tested negative) were ineligible. At each participating institution, the governing ethics committee approved the study, and written informed consent was obtained from all patients.
Treatment
Veltuzumab was administered by intravenous infusion once weekly for 4 consecutive weeks following protocol-specified limits for advancing the infusion rates (for details, see Appendix Table A1 , online only). Patients were premedicated each week with an antihistamine and antipyretic, but no corticosteroids.
Assessments
NHL subtypes were determined for each patient by WHO classification, 27 with Follicular Lymphoma International Prognostic Index and International Prognostic Index scores assigned for follicular lymphoma (FL) and nonfollicular lymphomas, respectively.
28,29 Tumor assessments were based on computed tomography scans (neck, thorax, abdomen, pelvis, other sites of known disease) and physical examinations at baseline, 4 and 12 weeks after last infusion and then every 3 months until disease progression, with bone marrow biopsy repeated only if positive at baseline to confirm a CR. Treatment responses were classified at each site by International Workshop Response Criteria, 30 as either CR, CRu, partial response (PR), stable disease, or progressive disease.
Safety was assessed by adverse events (AEs) classified by the Medical Dictionary for Regulatory Activities system organ class and preferred terms, serum chemistries, hematology, urinalysis, serum immunoglobulins, T-cell levels (CD3 ϩ ), and physical examinations. Laboratory and AE toxicity was graded according to National Cancer Institute Common Toxicity Criteria, version 3.0, with dose-limiting toxicity (DLT) defined as any treatment-related grade 3 or 4 events or grade 2 events of autoimmune reaction, bronchospasm, or generalized urticaria. Pharmacodynamics was assessed by blood B-cell levels (CD19 ϩ ). For pharmacokinetics and immunogenicity, enzyme-linked immunosorbent assay tests performed by the Sponsor measured serum levels of veltuzumab and any HAHAs, respectively. Pharmacokinetic parameters after last infusion were determined by WINNonlin 2.1 (Pharsight Corp, Mountain View, CA) using a single-compartment model.
Statistical Analysis
Response rates were summarized using descriptive statistics. Progression-free survival (PFS) was calculated from first infusion to disease progression, death, or last contact, whichever occurred earliest, with duration of response (DR) calculated from the onset of an objective response (OR; ie, CR, CRu, or PR) to the same events. The Kaplan-Meier method and the associated Greenwood's formula were used to generate PFS and DR survival curves and the CIs for the estimated medians. 
RESULTS
Eighty
Study Drug Administration
Three patients with early disease progression withdrew after two to three veltuzumab infusions, and one patient with small lymphocytic lymphoma (SLL) who had experienced hives and chills with previous rituximab withdrew after similar grade 1 to 2 reactions at the first infusion. The other patients completed all four infusions at their scheduled dose level, except for three patients, including one patient who prematurely terminated the first infusion at a reduced dose as a result of back pain and tightness of the throat, but received full doses given slowly at remaining infusions without event; one patient who completed initial infusions at full dose, but prematurely terminated the third and fourth infusions at reduced doses as a result of grade 2 reactions (pruritus, rash, hives, swollen tongue); and one patient who was inadvertently administered one infusion at the next higher dose level. The median first infusion times were 4.7 hours at 750 mg/m 2 , 3.1 hours at 375 mg/m 2 , and 1.8 to 2.4 hours at lower doses, whereas median times for subsequent infusions were 2.1 to 2.6 hours at 375 or 750 mg/m 2 , and 1.2 to 1.5 hours at lower doses (Appendix Table A1 ).
Treatment Response
The single patient with SLL who withdrew at first infusion was not assessed for efficacy. Across all histologies, the overall OR (CR ϩ CRu ϩ PR) and CR/CRu rates were 40.7% (10 CRs, seven CRus, and 16 PRs of 81 patients) and 21.0% (17 of 81 patients), respectively, whereas patients with FL had 43.6% (24 of 55) ORs and 27.3% (15 of 55) CRs/CRus, including 16.4% (nine of 55) CRs alone. Table 2 lists response rates by histology, dose level, and other factors.
For the 55 patients with FL (50 patients now having reached the study end point of disease progression and five patients in continuing follow-up at 15.9 to 37.6 months), the Kaplan-Meier estimated median PFS was 6.2 months (95% CI, 3.5 to 9.2 months). Of the 24 objective responders with FL, the Kaplan-Meier estimated median time from first infusion to the onset of an OR was 3.3 months (95% CI, 1.7 to 3.7 months), the median response duration was 10.2 months (95% CI, 6.0 to 22.6 months), and the median PFS was 15.2 months (95% CI, 9.5 to 28.2 months). For the 15 patients with FL who achieved CR/CRu, the Kaplan-Meier estimated median DR and PFS were 19.7 months (95% CI, 8.7 to 32.5 months) and 24.2 months (95% CI, 13.8 to 34.4 months), respectively. Kaplan-Meier PFS curves for the entire FL group and those with CRs/CRus are shown in Figure  1 . Although the sample sizes are small, response durability seemed similar at lower and higher dose levels, with five patients (one at 80 mg/m 2 ) having ongoing responses 15.9 to 37.6 months after starting veltuzumab. Among patients with nonfollicular lymphoma, the two CRs (one at 80 mg/m 2 ) and one case of long-term stable disease (all in marginal-zone lymphoma) are ongoing at 14.6 to 26.2 months.
AEs
Seventy-two patients had one or more AEs during the study. Of 51 patients with AEs considered at least possibly treatment related, there was only one grade 3 event, which was a laboratory finding of hypoglobulinemia that occurred without definitive explanation during long-term follow-up. Otherwise, all possibly treatment-related events were mild to moderate (grades 1 to 2), most of which were transient infusion-related symptoms occurring predominantly at first infusion. The most frequent events were fatigue (23%), pruritus (13%), fever (13%), headache (11%), asthenia (11%), dyspnea (10%), and cough (10%; Appendix Table A2 , online only).
Ten patients had serious AEs. None were considered even possibly treatment related, but instead were attributed to complications of underlying disease or other medical conditions. The serious AEs included one case of preexisting atrial fibrillation, three events during the treatment period (trauma, cellulitis after first infusion in patient entered with extensive psoriasis, pleurisy after second infusion related to early progressive disease), and six subsequent events that occurred within 12 weeks of treatment (decreased performance status, back pain, incidental finding of arteriovenous malformation) or during later follow-up (bladder tumor, pulmonary embolism, urinary fungal infection).
Sixteen patients had infections. Four patients had grade Ն 3 infections requiring intravenous antibiotics or multiple oral antibiotics (cellulitis, pleurisy, fungal urine infection, infection not otherwise specified), none attributed to veltuzumab. Otherwise, all infections were grade 1 to 2 events treated with oral medications and predominantly involving the respiratory tract, urinary tract, or sinuses. 
‫ء‬
Follicular grades: 1 (n ϭ 31), 2 (n ϭ 18), 3 (n ϭ 4), not specified (n ϭ 2). †Histologies: diffuse large B-cell lymphoma (n ϭ 7), mantle-cell lymphoma (n ϭ 7), marginal-zone lymphoma (n ϭ 6), small lymphocytic lymphoma (n ϭ 5), lymphoplasmacytoid lymphoma (n ϭ 2).
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Safety Laboratories
Blood samples for hematology and serum chemistries were obtained before each infusion, 4 and 12 weeks after the last infusion, and every 3 months during follow-up. No abnormal pattern of changes occurred, and few patients had increases in toxicity grades after treatment (Appendix Table A3 , online only). No cases of delayed neutropenia, including 41 patients monitored for at least 6 months.
Pharmacokinetics
Pharmacokinetics were analyzed for 72 patients, all of whom completed all four infusions at the intended dose. Table 3 summarizes the mean serum levels before and 30 minutes after each infusion, whereas Table 4 summarizes the mean pharmacokinetic parameters after last infusion. A subgroup analysis for patients with FL showed similar results (data not shown). In FL, median serum levels at each infusion were higher for responders than nonresponders (Appendix Table A4 , online only) and lower for patients with high versus low tumor burden (Appendix Table A5 , online only). Figure 2 graphs the time course of B-cell levels for 68 patients with nonelevated B-cell levels at baseline (1 to 256 cells/L) and at least one measurement during treatment. The results appear similar across dose levels, with depletion after first infusion, and returning toward baseline by 9 to 12 months. Nine other patients (including all five patients with SLL) who entered this study with elevated B-cell levels (572 to 14,712 cells/L) had a median 94% decrease with treatment that was short-lived (most increasing by 3 months).
Immunologic Changes
Quantitative serum immunoglobulin (Ig) and T-cell levels measured at baseline, before last infusion, 4 and 12 weeks later, and, in limited number of patients, in subsequent follow-up, showed no consistent pattern of clinically significant decreases, with median changes from baseline being small at most time points (typically Ͻ 5% for IgA and IgG, Ͻ 20% for IgM, and Ͻ 15% for T cells).
Immunogenicity (HAHA)
Seventy patients had at least one post-treatment serum sample at 4 weeks (n ϭ 58), 12 weeks (n ϭ 53), 6 months (n ϭ 8), or 1 year (n ϭ 2) after last infusion analyzed for HAHA by enzyme-linked immunosorbent assay. One patient with SLL with prior rituximab exposure was negative at study entry but developed elevated titers (3,380 ng/mL) 4 weeks after treatment without any apparent clinical consequence. All other samples were negative (Ͻ 50 ng/mL). 
DISCUSSION
As a humanized second generation anti-CD20 monoclonal antibody, veltuzumab shows differentiation from rituximab both structurally and functionally. Veltuzumab differs by one amino acid (aspartic acid instead of asparagine) in one complementarity-determining region, but has completely different framework regions.
22 Veltuzumab demonstrated slower off rates in three human lymphoma cell lines, and mutation studies confirmed that the difference was related to the single amino acid change. 22 Although antiproliferative, apoptotic, and antibody-dependent cellular cytotoxicity effects seemed similar in vitro, 21,22 veltuzumab demonstrated increased complementdependent cytotoxicity in one of three lymphoma cell lines and was significantly more effective in vivo than rituximab in three lymphoma models. 22 Even at very low doses, veltuzumab effectively depleted B cells in cynomolgus monkeys and controlled tumor growth in mice bearing human lymphoma xenografts. 21, 22 Our clinical data are consistent with this apparent improved potency, because veltuzumab was active even at 80 mg/m 2 , which represents approximately 20% of the standard 375 mg/m 2 rituximab dose. Veltuzumab treatment was well tolerated, with no serious infusion reactions nor increases in the frequency of more common infusion reactions despite short infusion times. Because the protocol limited the rate of infusions in this first study, we predict that even more rapid administrations are possible.
In this study, among the majority of patients with FL and prior exposure to rituximab-containing regimens, the 44% OR rate was similar to the 40% OR rate reported for patients who previously responded to rituximab, and the 27% CR/CRu rate (16% for CRs alone) compares favorably with the 11% CR reported in that same study. 31 The highest response rates with veltuzumab in FL occurred in the small number of rituximab-naïve patients (57% [four of seven] OR, 43% [three of seven] CR/CRu) and compares favorably with the 48% OR and 6% CR rates reported with rituximab in rituximab-naïve patients. 1 Importantly, veltuzumab responses, including CRs, also occurred in patients with FL who had received multiple prior rituximab-regimens or were at risk of less-favorable outcome (higher Follicular Lymphoma International Prognostic Index scores, elevated lactate dehydrogenase, tumor masses Ͼ 5 cm). The 10.2 months median DR found for FL responders in this study is comparable to the 11.2 months DR reported in patients with relapsed/refractory, indolent NHL after a first application of rituximab. 1, 32 Although a longer 15.0 months median DR was reported in patients re-treated with rituximab, 31,32 most had received one prior course of rituximab given as a single agent, whereas patients in this study had often received Post  39  9  59  13  94  22  194  35  474  33  Infusion 2  Pre  11  5  18  11  28  18  75  45  222  158  Post  48  15  86  31  125  44  276  90  632  99  Infusion 3  Pre  20  7  30  19  57  29  118  51  385  77  Post  55  15  92  44.4  140  49  335  91  801  29  Infusion 4  Pre  27  11  43  26  72  41  173  69  495  64  Post  68  25  100  37  170  67  404  105  996  66 multiple prior courses of rituximab given in combination with chemotherapy. The apparent greater number of CRs achieved with veltuzumab is also important, because patients with FL with CRs/CRus in this study generally had durable responses (median DR and PFS of 19.7 and 24.2 months, respectively), and five patients are still continuing long-lived responses (15.9 to 37.6 months). Among the nonfollicular histologies, veltuzumab achieved a significant overall OR rate of 35% (27% CRs/CRus) that varied by histology. In marginal-zone lymphoma (either extranodal mucosaassociated lymphoid tissue or nodal type disease), five (83%) of six patients had ORs, with two CRs/CRus (33%), one at 80 mg/m 2 , and with three long-term responses (15 to 24 months), one at only 80 mg/m 2 . In diffuse large B-cell lymphoma (DLBCL), all patients had previously received rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, yet three of seven patients (one at 80 mg/m 2 ) had PRs, yielding a 43% OR rate, which is comparable to the 37% Fig 2. B-cell levels for patients having nonelevated levels at entry and at least one measurement during the treatment period. Graphs reflect data available in each patient with blood samples to be collected at baseline, before infusions (Infs) 2, 3, and 4, at 4 and 12 weeks later, then at 3-month intervals for up to 12 months after last infusion. As a result of small patient numbers, results for the 750-mg/m 2 dose group have been combined with those of the 375-mg/m 2 dose group.
rate reported in rituximab-naïve patients with DLBCL with eight weekly doses of rituximab. 33 Thus veltuzumab may be useful in combination with chemotherapy in DLBCL, as found with rituximab.
5-7
Although less activity occurred in mantle-cell lymphoma (one PR at 120 mg/m 2 ), SLL (although elevated B cells were depleted), and lymphoplasmacytic lymphoma, patient numbers were small and further study is required, because the single-agent activity of rituximab in these entities is also more limited. 1, [34] [35] [36] At 375 mg/m 2 , the mean peak and trough serum antibody levels achieved with veltuzumab were comparable to values reported at this dose for rituximab. 37 Interestingly, among the patients with FL, we found the same relationship of higher serum levels in responders as well as in patients with nonbulky disease, as reported with rituximab.
37-39 At all dose levels here, B-cell depletion typically occurred after the first infusion, whereas mean antibody serum levels after the first infusion exceeded the 25-g/mL value associated with maintained efficacy. [37] [38] [39] In addition, veltuzumab remained in circulation after the last infusion, with half-lives that were similar at all dose levels, and at least as long as reported in rituximab studies.
37,39 These findings suggest that the lower veltuzumab doses were adequate to overcome the antigenic sink, thus supporting the demonstration of clinical activity observed at all dose levels in this study.
Although rituximab may have activity at lower doses, 40, 41 it was approved at 375 mg/m 2 , and even higher doses were accepted for clinical use without further evaluation of a dose-response effect or assessment of lower doses. Of the other second-generation anti-CD20 antibodies in clinical trials, the trend has been to explore antibody doses close to or higher than those typically given with rituximab. [17] [18] [19] [20] Using ofatumumab doses up to 1,000 mg resulted in treatmentrelated grade 3 events in 18% of patients with NHL at first infusion, which required up to 13 hours to complete. 19 As with rituximab, these other studies have not shown a clear dose-effect relationship, consistent with our findings with veltuzumab. Thus a better understanding of mechanisms of action, pharmacokinetics, and other patient factors is needed to optimize dosing. 39, 42 However, all doses of veltuzumab less than 375 mg/m 2 showed activity, consistent with animal studies, 22 and studies of shaving effects in chronic lymphocytic leukemia, 43, 44 which suggests lower doses should be explored. Lower doses also may be effective against low tumor burdens or minimal residual disease and therefore may be well suited for maintenance therapy or for B-cell-mediated autoimmune diseases, where the CD20 sink may be less and overly aggressive B-cell suppression may not be needed nor desirable. As such, these are reasonable choices for further clinical study. The findings of this first study are consistent with the structurefunction differentiation from rituximab seen in preclinical studies, 22 and the combination of excellent tolerability with shorter infusion times and activity at lower doses all suggest that veltuzumab has potentially significant clinical value. The lower amounts of antibody (80 to 200 mg/m 2 ) are also compatible with a subcutaneous route of administration, which may offer equivalent efficacy with greater convenience (as seen with alemtuzumab 45 ), and subcutaneous injections with veltuzumab are currently being explored in two clinical trials (NCT00546793 and NCT00547066). Abbreviation: ANC, absolute neutrophil count.
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‫ء‬
Continued deterioration from borderline grade 2 anemia at study entry to grade 3 levels 12 weeks after treatment. †Grade 3 cytopenia 12 weeks after treatment after chemotherapy initiated for disease progression. ‡Transient grade 3 ANC 12 weeks after treatment attributed to continued fluctuations from grade 2 levels at study entry. §Patient with chronic renal insufficiency and continued deterioration of grade 2 creatinine at study entry to grade 3 levels by 12 weeks after treatment. Results are based on data available in each patient with serum samples to be collected before and 30 minutes after each infusion. Patients with at least one index lesion Ͼ 5 cm in greatest transverse diameter are considered to have high tumor burden.
†Below lower level of quantitation.
